Sickle cell disease patient receives stem cell transplantation

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord(R) as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

NiCord(R) is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells.

Gamida Cell CEO Dr. Yael Margolin said, "The NiCord(R) study is a first step in broadening Gamida Cell's pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need."

Read the full article on Market Watch